By Rebecca Giblin, Anders Furze and Kimberlee Weatherall
For hundreds of years, we’ve been told patents help deliver big new inventions, such as life-saving drugs.
They are meant to be a bargain between the inventor and the public: tell us how your invention works, and we’ll give you a fixed time – a patent protection period – in which you’re the only person who can make use of it.
Such exclusive rights make it easier for inventors to profit from their investments in research and development, and in theory encourage innovation we wouldn’t get otherwise, which benefits us all.
We’ve long had to accept this bargain on faith. But those core assumptions about patents are increasingly being subject to empirical testing, and – as we detail in a new podcast starting this week – often coming up short.
Many claimed inventions likely don’t work
Consider the most basic assumption – that the public will benefit from patented technologies - both as products and services and as building blocks for more innovation. That’s meant to be achieved by inventors coming up with inventions that work, then telling the patent office how they work.
But research by Janet Freilich from Fordham University in the United States suggests there is a “replicability crisis” in patent claims that rivals those in other fields.
Freilich graded the experiments said to back up 500 life sciences patents against the requirements of the journal Nature – and found as many as 90% didn’t stack up and probably couldn’t be reproduced.
She says
patent law relies on the assumption that, when a patent is filed, it has been “reduced to practice” – meaning that the invention works. The reality is that most inventions likely do not work, casting serious doubt on this assumption.
One of the reasons is the way the patent system works.
Under the ‘first-to-file’ system, when two inventors are developing similar technologies, the inventor who gets to the patent office first gets the patent. Freilich argues this means that any experiments they do conduct will inevitably be quick and preliminary.
Worse still, only 45% of the patents she examined were backed up by any sort of experiment. The remaining 55% were supported only by speculative and hypothetical evidence. This is allowed under patent law at least in some countries, but it does raise questions about what exactly the public gets out of the system.
Research sometimes accelerates when patents expire
We’re also told we grant patents to “incentivise” (encourage and reward) the kind of work needed to get expensive products, like new drugs, to market.
But again, this theory doesn’t always match the practice.
Research led by John Liddicoat of King’s College London finds that in the development of many drugs, the most expensive trials (Phase II and Phase III) actually accelerate once patent protection expires, when universities and hospitals feel free to step in.
This raises a number of serious questions:
- why aren’t patents providing an incentive for patent holders to do these trials?
- should we shorten the length of patents to bring forward trials?
- are commercial organisations best suited for trials?
An AI-driven flood of low-quality patents
Artificial intelligence is set to make it easier to find, and perhaps automatically enforce patents, which could frighten away more genuine innovators.
Generative AI could also lead to more patents: in the words of the government agency IP Australia, it is likely to reduce “the barrier to creating novelty”. This could potentially overwhelm patent offices with even lower quality patents.
It is also likely to mean patent examiners can no longer rely on the default assumption that the claimed invention is solely the result of human exertion, raising the possibility of needing to rethink the patent bargain.
Invention matters more than ever
More and more, new research and new developments are telling us we can no longer take the claims made for the patent system on faith.
Urgent challenges – including climate change, infectious diseases, political polarisation and artificial intelligence – all require cutting-edge science that can be put to work quickly and at scale to solve real-world problems.
That makes this an ideal time to talk about whether our patent system is best equipped for that task, exploring a range of options for finding and applying the innovations we need - and bringing in voices and perspectives that are too often marginalised in intellectual property debates.
This article is republished from the Conversation
Read the original article here
What is happening in India?
Over the years, India has understood the importance of strong patent systems for the growth of industry and commerce, trying to maintain a balance between exclusive rights of the inventor and the public interest. As per the Indian Patent Office Annual Report 2021-22, 66,440 patent applications were filed in India. Out of which, 66,572 applications were examined, out of which 30,073 were granted and 35,990 applications were disposed of. As of March 31, 2022, the number of patents in force was 115916 out of which 19700 belonged to Indian patentees.
The patents granted in the field pharmaceuticals and medical field reflect the country's priority to excel in’s healthcare, which in return benefits its citizens.
The question here is not how many of the patents are granted or rejected, the question is how many of the granted patents have been used commercially. Under section 146 of the patent act, 55014 statements on the working of patents were received in Form 27 during the year and 9616 patents were reported as working.
For years IP as a legal mechanism has played a crucial role in incentivising innovation and creativity by providing rights to creators and innovators for a fixed period of time. However, these prolonged exclusive rights also stifle innovation and creativity by inhibiting the free exchange of ideas and hindering the free dissemination of knowledge.
A delicate balance is required between these incentives and access to knowledge in the fast-changing dynamic world of disruptive technology and innovation. Perhaps it is time to reconsider the terms of these laws and carefully consider the limitations and exceptions.